Abstract：
:We present the long-term results of three consecutive clinical trials (Total Therapy studies 11, 12 and 13A) conducted for children with newly diagnosed acute lymphoblastic leukemia (ALL) between 1984 and 1994. In study 11 (1984-1988), the overall event-free survival rates (+/-1 s.e.) were 71.8 +/- 2.4% and 69.3 +/- 2.4%, and the cumulative risks of isolated central nervous system (CNS) relapse 5.6 +/- 1.2% and 5.9 +/- 1.3%, at 5 and 10 years, respectively. In study 12 (1988-1991), event-free survival rates were 67.6 +/- 3.4% and 61.5+/- 9.0%, and isolated CNS relapse rates were 10.4 +/- 2.3% and 10.4 +/- 2.3%, respectively. Early intensive intrathecal therapy in study 13A (1991-1994) has yielded a very low 5-year isolated CNS relapse rate of 1.2 +/- 0.9%, boosting the 5-year event-free survival rate to 76.9 +/- 3.3%. Factors consistently associated with an adverse prognosis included male sex, infant or adolescent age group, leukocyte count >100 x 10(9)/l, nonhyperdiploidy karyotype and poor early response to treatment. Risk classification based on age and leukocyte count had prognostic significance in B-lineage but not T-lineage ALL. Early therapeutic interventions or modifications for patients with specific genetic abnormalities or persistent minimal residual leukemia may further improve long-term results.
journal_name
Leukemiajournal_title
Leukemiaauthors
Pui CH,Boyett JM,Rivera GK,Hancock ML,Sandlund JT,Ribeiro RC,Rubnitz JE,Behm FG,Raimondi SC,Gajjar A,Razzouk B,Campana D,Kun LE,Relling MV,Evans WEdoi
10.1038/sj.leu.2401938subject
Has Abstractpub_date
2000-12-01 00:00:00pages
2286-94issue
12eissn
0887-6924issn
1476-5551journal_volume
14pub_type
杂志文章,meta分析相关文献
LEUKEMIA文献大全abstract：:Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here we isolated a high-affinity (HA) f...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2016.35
更新日期：2016-06-01 00:00:00
abstract：:We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfav...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2010.234
更新日期：2011-01-01 00:00:00
abstract：:The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2011.71
更新日期：2011-07-01 00:00:00
abstract：:All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading example of targetted drugs for inducing an in vivo differentiation of malignancy (1,2). A fixed dose of 45 mg/m2/day was proposed for the treatment of patients (3), according to the results obtained by retinoic acid derivatives...
journal_title：Leukemia
pub_type： 临床试验,杂志文章
doi：
更新日期：1994-01-01 00:00:00
abstract：:We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2400732
更新日期：1997-08-01 00:00:00
abstract：:A higher frequency of acute promyelocytic leukemia (APL) has been noted in countries of Southern Europe and among 'Latino' patients of the United States with acute myeloid leukemia (AML). In order to discover whether there is any genetic predisposition to the disease, we analyzed microsatellites flanking PML and RARal...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2402525
更新日期：2002-07-01 00:00:00
abstract：:Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph+ leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small f...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2016.174
更新日期：2017-01-01 00:00:00
abstract：:The fusion transcript AML1/ETO corresponding to translocation t(8;21)(q22;q22) can be found in approximately 7-12% of childhood de novo AML. Despite the favorable prognosis, some of these patients relapse. Most of MRD studies so far were performed on adults treated not uniformly. Therefore, we analyzed the follow-up o...
journal_title：Leukemia
pub_type： 杂志文章,多中心研究
doi：10.1038/sj.leu.2402959
更新日期：2003-06-01 00:00:00
abstract：:Oncoprotein 18 (Op18) is a major cystolic phosphoprotein constituent of leukemia cells. There is cumulative evidence that suggests a role for Op18 in integrating signals from diverse pathways involved in cell growth. Op18 phosphorylation is induced with proliferation in a variety of cell types, and is essential for ce...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2400792
更新日期：1997-10-01 00:00:00
abstract：:Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were...
journal_title：Leukemia
pub_type： 杂志文章,多中心研究
doi：10.1038/leu.2011.196
更新日期：2012-01-01 00:00:00
abstract：:Chronic lymphocytic leukemia (CLL) remains incurable with chemoimmunotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential for cure. We assessed the outcomes of 108 CLL patients undergoing first allogeneic HSCTs, 76 with reduced-intensity (RIC) and 32 with myeloablative conditioni...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2012.228
更新日期：2013-02-01 00:00:00
abstract：:The configuration of the immunoglobulin heavy and light chain genes and of the T cell receptor (TCR) beta region was examined in a series of patients with hairy cell leukemia (HCL) and compared with the findings in B cell chronic lymphocytic leukemia (B-CLL). In all cases of HCL and B-CLL studied a rearrangement of th...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1987-04-01 00:00:00
abstract：:The in vitro effects of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR, fenretinide) on primary B-cell chronic lymphocytic leukemia (CLL) cells from previously untreated CLL patients were investigated. 4HPR promoted the intrinsic apoptotic pathway by reactive oxygen species (ROS) generation and was accompa...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2012.98
更新日期：2012-10-01 00:00:00
abstract：:CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1995-09-01 00:00:00
abstract：:Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2015.328
更新日期：2016-04-01 00:00:00
abstract：:Resistant AML encompasses two groups of patients: those with refractory leukemia and those whose leukemia has relapsed. Refractory leukemia is disease that does not respond to initial induction chemotherapy with cytarabine and an anthracycline. Patients with refractory leukemia are likely to have disease with adverse ...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：
更新日期：1998-09-01 00:00:00
abstract：:We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years fol...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2011.29
更新日期：2011-06-01 00:00:00
abstract：:We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of study population), 5-19% (n = 1045, 66%), and ≥20% (n = 298, 19%). Heart and renal involvement were more and less prevalent, respecti...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/s41375-019-0655-x
更新日期：2020-04-01 00:00:00
abstract：:Reciprocal rearrangements of the MLL gene are among the most common chromosomal abnormalities in both Acute Lymphoblastic and Myeloid Leukemia. The MLL gene, located on the 11q23 chromosomal band, is involved in more than 40 recurrent translocations. In the present study, we describe the development and validation of ...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2403439
更新日期：2004-09-01 00:00:00
abstract：:Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells. To investigate whether chromosomal instability and/or DNA repair defects are involved in the development of MDS, we measured the micronucleus (MN) frequency in peripheral blood lymphocytes exposed to various doses of X-rays, using a cytok...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2402703
更新日期：2002-11-01 00:00:00
abstract：:Cellular stressors induce various outcomes including inhibition of cell proliferation and cell death. Sodium salicylate (SA), a plant stress hormone, can suppress the proliferation or cause apoptosis in certain mammalian cancer cells. Plant stress hormones are activators of cellular responses, including cell death, to...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2402419
更新日期：2002-04-01 00:00:00
abstract：:The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis. The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation. Several proteasome inhibitors exert anti-tumour activity in vivo and potently induce apoptosis in tumour...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：10.1038/sj.leu.2402417
更新日期：2002-04-01 00:00:00
abstract：:The response of human acute myelogenous leukemia (AML) cells to four different hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 beta (IL-1beta), interleukin-3 (IL-3), and stem cell factor (SCF)) and the relationship of the proliferative response of the AML cells to...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2400870
更新日期：1997-12-01 00:00:00
abstract：:To evaluate current detection methods for FIP1L1-PDGFRA in hypereosinophilic syndrome (HES), we developed a means to rapidly amplify genomic break points. We screened 202 cases and detected genomic junctions in all samples previously identified as RT-PCR positive (n=43). Genomic fusions were amplified by single step P...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2008.309
更新日期：2009-02-01 00:00:00
abstract：:Recurrent chromosomal rearrangements are observed in many leukemia subtypes. Recently, it has been shown that several of these translocations/inversions were associated with the loss of sequences located in the vicinity of the chromosomal breakpoints. So far, such deletions have not been described for the t(8;21) tran...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2402585
更新日期：2002-09-01 00:00:00
abstract：:Monoclonal antibody (mAb) M195 is a mouse IgG2a reactive with a myelomonocytic differentiation antigen found on early myeloid cells and monocytes. The reactivity of M195 with fresh hematopoietic neoplasms in the blood or bone marrow from 227 patients at Memorial Hospital was determined by flow cytometry. M195 was posi...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1989-06-01 00:00:00
abstract：:Tumor-infiltrating T-lymphocytes (T-TIL) are putative mediators of tumor containment that exhibit unique specificity for autologous tumor cells. The magnitude of T-TIL response in biopsy specimens from patients with B-cell lymphoma has been suggested as an independent predictor of clinical outcome. Since recognition o...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1993-03-01 00:00:00
abstract：:The hematopoietic growth factors are glycoproteins that can be produced by recombinant DNA technology. They have many potential clinical uses in acute leukemia; several areas have been explored extensively and much data are available from clinical trials. Other areas are of potential interest, but have a paucity of cl...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：10.1038/sj.leu.2400592
更新日期：1997-03-01 00:00:00
abstract：:Recent studies suggest that most cases of myelodysplastic syndrome (MDS) are clonally heterogeneous, with a founding clone and multiple subclones. It is not known whether specific gene mutations typically occur in founding clones or subclones. We screened a panel of 94 candidate genes in a cohort of 157 patients with ...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2013.58
更新日期：2013-06-01 00:00:00
abstract：:Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：10.1038/s41375-018-0036-x
更新日期：2018-06-01 00:00:00
